USA flag logo/image

An Official Website of the United States Government

OTHER FUNCTIONS TOPIC 255, PHASE II, TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
N44CO120093
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
Small Business Information
SENSOPATH TECHNOLOGIES, INC.
920 Technology Blvd STE B BOZEMAN, MT 59718-4001
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: OTHER FUNCTIONS TOPIC 255, PHASE II, TARGETED TWO-PHOTON PHOTODYNAMIC THERAPY TRIADS
Agency: HHS
Contract: N44CO120093
Award Amount: $1,499,896.00
 

Abstract:

The objectives of this proposal are to further preclinical development of unique two-photon-activated photodynamic therapy (TPPDT) triads that incorporate a nontoxic porphyrin photosensitizer, a tumor targeting group, and an imaging functionality, providing for noninvasive image-guided treatment of recurrent and refractory head and neck tumors deep below the skin surface that currently have low survival rates and few treatment options. SensoPath Technologies will develop a detailed understanding of the dosimetry of the process, involving the interplay of targeting the receptor on the tumor surface, the delivery of pulsed near infrared (NIR) laser light in the range 800-840 nm, the method of drug delivery with optimized concentration, and the role of oxygen level in the tumor s blood supply. Image-guided TPPDT, in which the irradiation of the tumor is controlled by its digitized image throughout the 3D volume of the tumor, will define and incorporate optical tumor margins to ensure that the entire tumor is treated. Planned image-defined tumor treatment in tissue phantoms and xenograft SCID mouse models will provide the information necessary to effectively treat deep spontaneous head and neck tumors in companion canines as an out-patient low-cost model for humanclinical treatment with rapid recovery, little scarring and no post-PDT light sensitivity.

Principal Investigator:

Charles Spangler
406-587-6338
CHARLES.SPANGLER@SENSOPATH.COM

Business Contact:

Charles Spangler
406-587-6338
CHARLES.SPANGLER@SENSOPATH.COM
Small Business Information at Submission:

SENSOPATH TECHNOLOGIES, INC.
920 Technology Blvd BOZEMAN, MT 59718-

EIN/Tax ID: 999999999
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No